Why Edgewise Therapeutics Stock Topped the Market on Tuesday

By Eric Volkman – Mar 17, 2026 at 6:31PM ESTKey PointsShe raised her price target by $11 per share.In her view, the company's No. 1 pipeline drug has vast potential.A significant price target boost from an analyst at a prominent U.S. bank was the main catalyst behind Edgewise Therapeutics' (EWTX +2.18%) rise on the stock market on Tuesday. Investors were encouraged enough by the move to bid the biotech's share price up by more than 2%, handily beating the 0.3% rise of the benchmark S&P 500 index. $11 improvement The pundit behind the increase was Tessa Romero of JPMorgan Chase unit JPMorgan. Well before market open Tuesday, she raised her Edgewise price target to $45 per share from $34. She maintained her overweight (read: buy) recommendation on the stock. Image source: Getty Images. According to reports, the analyst feels that Edgewise has several investigational programs that could vault it ahead. Romero noted renewed interest in the company's EDG-7500, a novel pipeline drug targeting the heart disorder hypertrophic cardiomyopathy (HCM). In what surely isn't a coincidence, last week Edgewise published long-term data from an open-label study of muscular dystrophy treatment sevasemten. The data showed that patients suffering from one type of muscular dystrophy, Becker, showed stabilization of function when administered the drug. This, the company wrote, is "in marked contrast to the functional decline expected from Becker natural history data." ExpandNASDAQ: EWTXEdgewise TherapeuticsToday's Change(2.18%) $0.65Current Price$30.43Key Data PointsMarket Cap$3.2BDay's Range$30.35 - $31.5452wk Range$10.60 - $31.82Volume46KAvg Vol1.2M Double dose It's impressive when a biotech has only one high-potential medicine in advanced development; Edgewise has two. What's more, it's developing another two in the high-demand cardiovascular segment. All this makes the company a standout in the biotech sector and an exciting business to watch.Read NextFeb 9, 2026 •By Eric VolkmanWhy Edgewise Therapeutics Stock Crushed the Market on MondayDec 24, 2025 •By Eric VolkmanWhy Edgewise Therapeutics Stock Rocked the Market TodayMay 2, 2025 •By Eric VolkmanWhy Edgewise Therapeutics Stock Popped This WeekSep 19, 2024 •By James BrumleyWhy Edgewise Therapeutics Stock Is Up 50% on ThursdayAbout the AuthorEric Volkman is a contributing Motley Fool finance and stock market analyst. Previously, Eric was an equities analyst at European investment bank Raiffeisen Capital and Investment. He’s also been a freelance finance writer since 1995. He studied at Susquehanna University.TMFVolkmanStocks MentionedEdgewise TherapeuticsNASDAQ: EWTX$30.43(+2.18%)+$0.65JPMorgan ChaseNYSE: JPM$286.59(+0.15%)+$0.43*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.